



NEMESIS

NOVEL EFFECT BIOMARKERS FOR METABOLIC DISRUPTORS: EVIDENCE ON HEALTH IMPACTS TO ANSWER SCIENCE AND POLICY NEEDS

WHAT WE STUDY

How exposure to metabolism disrupting chemicals (MDCs) present in the environment, food, and consumer products alter our body's normal metabolism processes and cause diseases, such as fatty liver and type 2 diabetes.

OBJECTIVE 3

Study human exposure to MDCs and identify novel biomarkers of exposure.

OBJECTIVE 2

Study the adverse effects of MDCs in target organs.

OBJECTIVE 1

Generate a unified approach to identify MDCs.

OBJECTIVE 4

Improve the risk assessment of MDCs.

OBJECTIVE 5

Increase awareness of MDCs and promote positive health behaviors.



HOW TO TACKLE THE NEMESIS

- Identify relevant MDC-mixtures from human biomonitoring data across Europe
- Use state-of-the-art *in vitro* and *in vivo* methods to study the mechanisms of disruption and identify novel biomarkers of exposure
- Improve risk assessment of MDCs
- Engage citizens in the development of chemical policies

PROJECT DETAILS

NEMESIS project is funded by the European Union, Horizon Europe programme.

Grant Agreement no.: 101137405

Duration: 1.1.2024 - 31.12.2028

Grant amount: 7 881 685.25 €

Project coordination:

Professor Jaana Rysä

University of Eastern Finland,

School of Pharmacy

jaana.rysa@uef.fi



Funded by
the European Union

NEMESIS

Project partners



Dr. Margarete Fischer-Bosch
Institut für Klinische Pharmakologie



Karolinska
Institutet

